Premium
Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature
Author(s) -
Deutschbein Timo,
Fassnacht Martin,
Weismann Dirk,
Reincke Martin,
Mann Klaus,
Petersenn Stephan
Publication year - 2015
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.12590
Subject(s) - dacarbazine , medicine , vincristine , regimen , progressive disease , cyclophosphamide , chemotherapy , chemotherapy regimen , surgery , adverse effect , gastroenterology
Summary Objective Malignant phaeochromocytomas are rare and highly aggressive tumours. This retrospective study evaluated the outcome of combined chemotherapy with cyclophosphamide, vincristine and dacarbazine (also known as CVD regimen). Methods Patients with histologically and radiologically confirmed malignant phaeochromocytoma who were treated with the CVD regimen for progressive disease were retrospectively identified from chart review. Treatment cycles were usually repeated at 21‐day intervals, with cyclophosphamide (750 mg/m 2 ), vincristine (1·4 mg/m 2 ) and dacarbazine (600 mg/m 2 ) on day 1, and dacarbazine only (600 mg/m 2 ) on day 2. The main outcome measures were best response during treatment and progression‐free survival. Results Eight patients (4 males; median age 55·5 (range 31–77) years) with progressive disease underwent a median of 6 (range 3–11) cycles. Best treatment responses were as follows: partial response, n = 2 (25%); stable disease, n = 3 (38%); and progressive disease, n = 3 (38%). The median progression‐free survival was 5·4 (range 2·5–26·8) months. After the initial administration of 6 cycles, two patients received a second course of chemotherapy with another 6 cycles after new progressive disease had been detected. Subsequently, these patients were progression‐free for another 6·0 and 6·4 months. Mild gastrointestinal symptoms and fatigue were the most common adverse events. Conclusion Although objective tumour response rates were lower than previously reported in small series, the CVD regimen allowed disease stabilization for a substantial period of time and may therefore be considered as a treatment option in advanced stages. To improve disease outcome, however, new therapeutic approaches and larger multicentre studies are needed.